Filing Flows

Filing Flows › Companies › Arcadia Biosciences › Cash flow

Arcadia Biosciences cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$319K in Q2 2026 · −$2.5M over twelve months

Operating cash flow−$319K
Free cash flow−$319K

Analysis

In Q2 2026, Arcadia Biosciences generated −$319K of operating cash flow. That is $1.7M more than in Q2 2025 (−$2.0M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$2.5M; the largest uses were operating cash flow ($2.5M); besides operations, cash came from other financing ($5.3M), shares issued ($1K); the cash balance rose by $2.8M.

Operating cash flow was −$319K against net income of −$6.3M. The largest differences: payables +$288K, receivables −$134K, prepaid and other assets +$112K.

Free cash flow

Arcadia Biosciences: free cash flow by quarterArcadia Biosciences: free cash flow by quarter−$1.8MQ3 2024−$2.2MQ4 2024−$1.6MQ1 2025−$2.0MQ2 2025−$257KQ3 2025−$822KQ4 2025−$1.1MQ1 2026−$319KQ2 2026
Operating cash flow less capital spending.
Arcadia Biosciences: operating cash flow against capital spendingArcadia Biosciences: operating cash flow against capital spendingOperating cash flowCapital spending−$1.8M$0Q3 2024−$2.2M$0Q4 2024−$1.6M$0Q1 2025−$2.0M$0Q2 2025−$257K$0Q3 2025−$822K$0Q4 2025−$1.1M$0Q1 2026−$319K$0Q2 2026
Latest (Q2 2026): Operating cash flow −$319K, Capital spending $0.

Capital allocation, year by year

Arcadia Biosciences: where the cash came from (up) and went (down), by fiscal yearArcadia Biosciences: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingAcquisitionsFY2021: Operating cash flow −$25.9MFY2021: Net borrowing −$2.1MFY2021: Shares issued $39KFY2021: Asset sales $19KFY2021: Capital spending −$1.0MFY2021: Acquisitions −$4.2M$58KFY2021FY2022: Operating cash flow −$14.0MFY2022: Shares issued $7KFY2022: Asset sales $920KFY2022: Capital spending −$72K$927KFY2022FY2023: Operating cash flow −$15.3MFY2023: Shares issued $12KFY2023: Asset sales $115KFY2023: Capital spending −$5K$127KFY2023FY2024: Operating cash flow −$9.6MFY2024: Shares issued $9KFY2024: Asset sales $334KFY2024: Capital spending −$16K$343KFY2024FY2025: Operating cash flow −$4.7MFY2025: Shares issued $6K$6KFY2025
Over these 5 years operating cash flow totalled −$69.5M; the largest uses were operating cash flow ($69.5M) and acquisitions ($4.2M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$4.2M
Debtnone
Net cash$4.2M
Cash runway20 months

Arcadia Biosciences is burning cash: its operations consume cash, a free cash flow of −$2.5M a year at the current rate against $4.2M of cash and investments: a runway of about 20 months before any new financing.

Where the cash came from and went

Arcadia Biosciences: sources (+) and uses (−) of cash, Q2 2026Arcadia Biosciences: sources (+) and uses (−) of cash, Q2 2026Other financing$3.5MCash drawn (+) / kept (−)−$3.2MOperating cash flow−$319K
Arcadia Biosciences: sources (+) and uses (−) of cash, TTM to Q2 2026Arcadia Biosciences: sources (+) and uses (−) of cash, TTM to Q2 2026Other financing$5.3MCash drawn (+) / kept (−)−$2.8MOperating cash flow−$2.5MNot reconciled−$39KShares issued$1K

From profit to cash

Arcadia Biosciences: net income to operating cash flow, Q2 2026Arcadia Biosciences: net income to operating cash flow, Q2 2026Net income−$6.3MStock-based pay$14KReceivables−$134KInventory−$90KPayables$288KPrepaid and other assets$112KOperating cash flow−$319K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowShares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$319K—−$3.2M−$319K
Q1 2026−$1.1M—−$695K−$1.1M
Q4 2025−$822K—$861K−$822K
Q3 2025−$257K$1K$256K−$257K
Q2 2025−$2.0M—$1.8M−$2.0M
Q1 2025−$1.6M$5K$1.1M−$1.6M
Q4 2024−$2.2M—−$306K−$2.2M
Q3 2024−$1.8M$4K$1.6M−$1.8M

Arcadia Biosciences: income statement and cash flow

Arcadia Biosciences, Q2 2026: revenue $1.4M (-0.8% year over year), operating margin -34.4%. The chart follows the revenue to costs, profit and cash.

Arcadia Biosciences: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.